Affordable Access

deepdyve-link deepdyve-link
Publisher Website

A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.

Authors
  • Noyan-Ashraf, Mohammad Hossein
  • Shikatani, Eric Akihiko
  • Schuiki, Irmgard
  • Mukovozov, Ilya
  • Wu, Jun
  • Li, Ren-Ke
  • Volchuk, Allen
  • Robinson, Lisa Annette
  • Billia, Filio
  • Drucker, Daniel J
  • Husain, Mansoor
Type
Published Article
Journal
Circulation
Publisher
Ovid Technologies Wolters Kluwer -American Heart Association
Publication Date
Jan 01, 2013
Volume
127
Issue
1
Pages
74–85
Identifiers
DOI: 10.1161/CIRCULATIONAHA.112.091215
PMID: 23186644
Source
Medline
License
Unknown

Abstract

Weight-neutral treatment with a glucagon-like peptide-1 analog activates several cardioprotective pathways, prevents HFD-induced insulin resistance and inflammation, reduces monocyte vascular adhesion, and improves cardiac function in vivo by activating AMP-activated protein kinase. These data support a role for glucagon-like peptide-1 analogs in limiting the cardiovascular risks of obesity.

Report this publication

Statistics

Seen <100 times